• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Merck moving to Phase 2 study of drug-eluting implant to prevent HIV infection

March 8, 2021 By Sean Whooley

MerckMerck (NYSE:MRK) today announced positive results from a Phase 1 study of its subdermal drug-eluting implant for preventing HIV-1 infection.

The investigational implant has the potential for extended administration of islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection, according to a news release.

Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) being valuated for both the treatment of HIV-1 infection in combination with other antiretroviral agents, as well as for the prevention of HIV-1 infection as a single agent.

Study results, presented by Merck at the 2021 Conference on Retroviruses and Opportunistic Infections showed that the implant achieved active drug concentrations above the pre-specified pharmacokinetics (PK) threshold at 12 weeks across the three doses (48 mg, 52 mg and 56 mg) studied.

The study included eight participants in each dosage group, plus 12 in the placebo group, with the implant removed after 12 weeks and an evaluation continuing for eight weeks thereafter. At 12 weeks, all three doses resulted in mean islatravir triphosphate concentrations above the target threshold.

Results also showed that the implant is projected to provide drug concentrations likely above the threshold for one year at the 56 mg dose. In the study, 67% of participants reported at least one implant site adverse event, although all were mild or moderate in severity and none resulted in discontinuations. Common adverse events included erythema, tenderness/pain, pruritus and induration. The most common one not related to the implant site was headache, which affected six participants.

The findings in the study have led to Merck’s plans to initiate a Phase 2 trial to continue exploring the potential of a subdermal implant containing islatravir as a long-acting option for PrEP for up to 12 months.

“We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen for islatravir using a subdermal implant,” Merck Research Laboratories VP of global clinical development Dr. Joan Butterton said in the news release. “We know that PrEP can have a positive impact in curbing the spread of HIV and are looking forward to evaluating our implant further with the goal of developing new long-term options for HIV prevention.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Pharmaceuticals Tagged With: HIV, Merck

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS